amifostine anhydrous has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 13 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the radiation dose-response relationship on salivary dysfunction and quality of life (QOL) over time in patients with lymphoma receiving radiation therapy (RT) to the head and neck (H&N)." | 2.74 | A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. ( Hickey, G; Killion, L; Martin, C; Mauch, PM; Ng, AK; Rodrigues, NA; Silver, B; Stevenson, MA, 2009) |
| "Thirty-five patients (20 with non-Hodgkin lymphoma, 12 with Hodgkin disease, and 3 with acute myelogenous leukemia) who underwent autologous stem cell transplantation were conditioned with total body irradiation 2 Gy twice daily on days -8 through -6; cyclophosphamide 6 g/m(2), etoposide 1." | 2.71 | Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. ( Gabriel, DA; Harvey, D; Kirby, SL; Krasnov, C; Moore, DT; Serody, JS; Shea, TC, 2005) |
| "Amifostine can be given safely at a dose of 910 mg/m2 four times in 1 day in combination with HD-CTX." | 2.70 | Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide. ( Bosshard, M; Cavalli, F; Egger, HP; Gabutti, L; Ghielmini, M; Kiess, M; Pampallona, S; Sessa, C; Van der Bosch, S, 2001) |
| " One patient died after the first CHOP administration because of anthracycline-related acute cardiomyopathy (corresponding to a toxic death rate of 2." | 2.70 | Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study. ( Budach, V; Eucker, J; Genvresse, I; Krüger, L; Lange, C; Possinger, K; Schweigert, M; Sezer, O; Späth-Schwalbe, E, 2002) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rodrigues, NA | 1 |
| Killion, L | 1 |
| Hickey, G | 1 |
| Silver, B | 1 |
| Martin, C | 1 |
| Stevenson, MA | 1 |
| Mauch, PM | 1 |
| Ng, AK | 1 |
| Gómez, HL | 1 |
| Samanéz, C | 1 |
| Campana, F | 1 |
| Neciosup, SP | 1 |
| Vera, L | 1 |
| Casanova, L | 1 |
| Leon, J | 1 |
| Flores, C | 1 |
| de Mendoza, FH | 1 |
| Casteñeda, CA | 1 |
| Pinto, JA | 1 |
| Vallejos, CS | 1 |
| Phillips, GL | 1 |
| Meisenberg, BR | 1 |
| Reece, DE | 1 |
| Adams, VR | 1 |
| Badros, AZ | 1 |
| Brunner, JL | 1 |
| Fenton, RG | 1 |
| Filicko, J | 1 |
| Grosso, DL | 1 |
| Hale, GA | 1 |
| Howard, DS | 1 |
| Johnson, VP | 1 |
| Kniska, A | 1 |
| Marshall, KW | 1 |
| Mookerjee, B | 1 |
| Nath, R | 1 |
| Rapoport, AP | 1 |
| Sarkodee-Adoo, C | 1 |
| Takebe, N | 1 |
| Vesole, DH | 1 |
| Wagner, JL | 1 |
| Flomenberg, N | 1 |
| Gabriel, DA | 1 |
| Shea, TC | 1 |
| Serody, JS | 1 |
| Moore, DT | 1 |
| Kirby, SL | 1 |
| Harvey, D | 1 |
| Krasnov, C | 1 |
| Li, QB | 1 |
| Tang, XQ | 1 |
| Zhao, ZG | 1 |
| Wang, HX | 1 |
| You, Y | 1 |
| Chen, ZC | 1 |
| Zou, P | 1 |
| Cagnoni, PJ | 1 |
| Jones, RB | 1 |
| Bearman, SI | 1 |
| Ross, M | 1 |
| Hami, L | 1 |
| Franklin, WA | 1 |
| Capizzi, R | 1 |
| Schein, PS | 1 |
| Shpall, EJ | 1 |
| Poloni, A | 1 |
| Leoni, P | 1 |
| Curzi, L | 1 |
| Cantori, I | 1 |
| Mancini, S | 1 |
| Montanari, M | 1 |
| Masia, MC | 1 |
| Olivieri, A | 1 |
| De Souza, CA | 1 |
| Santini, G | 1 |
| Marino, G | 1 |
| Nati, S | 1 |
| Congiu, AM | 1 |
| Vigorito, AC | 1 |
| Damasio, E | 1 |
| Genvresse, I | 2 |
| Lange, C | 2 |
| Schanz, J | 1 |
| Schweigert, M | 2 |
| Harder, H | 1 |
| Possinger, K | 2 |
| Späth-Schwalbe, E | 2 |
| Ghielmini, M | 1 |
| Van der Bosch, S | 1 |
| Bosshard, M | 1 |
| Pampallona, S | 1 |
| Gabutti, L | 1 |
| Egger, HP | 1 |
| Kiess, M | 1 |
| Cavalli, F | 1 |
| Sessa, C | 1 |
| Emmanouilides, C | 1 |
| Territo, M | 1 |
| Andrey, J | 1 |
| Mason, J | 1 |
| Krüger, L | 1 |
| Eucker, J | 1 |
| Sezer, O | 1 |
| Budach, V | 1 |
| Coia, L | 1 |
| Krigel, R | 1 |
| Hanks, G | 1 |
| Comis, R | 1 |
| Algazy, K | 1 |
| Peters, R | 1 |
| McCulloch, W | 1 |
| Schien, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients[NCT00003425] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 1997-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 trials available for amifostine anhydrous and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2009 |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.
Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2012 |
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Topics: Adult; Amifostine; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Hematopoiet | 2004 |
Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies.
Topics: Acute Disease; Adolescent; Adult; Amifostine; Cytoprotection; Female; Graft Survival; Hematopoietic | 2005 |
Use of amifostine in bone marrow purging.
Topics: Adult; Amifostine; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Cyclophospham | 1996 |
Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytoprotection; | 2000 |
Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide.
Topics: Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents, Alkylating; Bone Marrow; Cyclophosphamid | 2001 |
A randomized phase II study of amifostine used as stem cell protectant in non-hodgkin lymphoma patients receiving cisplatin-based salvage chemotherapy prior to stem cell transplant.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; He | 2001 |
Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2002 |
A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies.
Topics: Amifostine; Combined Modality Therapy; Drug Evaluation; Humans; Leukemia, Lymphocytic, Chronic, B-Ce | 1992 |
3 other studies available for amifostine anhydrous and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
[Role of amifostine against the effect of etoposide on non-Hodgkin lymphoma bone marrow derived mesenchymal stem cells: an in vitro experiment].
Topics: Adult; Amifostine; Antigens, CD; Apoptosis; Bone Marrow Cells; Cell Proliferation; Cell Separation; | 2007 |
Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery.
Topics: Amifostine; Animals; Bone Marrow Purging; Cell Survival; Cells, Cultured; Colony-Forming Units Assay | 1999 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |